Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1842164
PUBLISHER: Grand View Research | PRODUCT CODE: 1842164
Japan Autoimmune Disease Diagnostics Market Size, Share & Trends Analysis Report By Test (Systemic Autoimmune Disease Diagnostics, Localized Autoimmune Disease Diagnostics), By Product, By Test Type, By End Use, And Segment Forecasts, 2025 - 2033
PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Market Size & Trends:
The Japan autoimmune disease diagnostics market size was estimated at USD 365.49 million in 2024 and is expected to reach USD 640.45 million by 2033, growing at a CAGR of 6.6% from 2025 to 2033. As the world's fastest-aging nation, with over 29% of its population aged 65 or older, Japan faces a rising prevalence of conditions such as rheumatoid arthritis and autoimmune pancreatitis. This fuels demand for ANA tests, autoantibody panels, and advanced molecular assays. Growth is further supported by innovations in multiplex immunoassays, AI, and biomarker discovery, alongside strong academic-industry collaborations. Partnerships, such as those involving Sysmex, MBL, and Autobio Diagnostics, enhance precision, scalability, and early disease detection.
According to the Statistics Bureau of Japan (October 2023), the country's population stood at 124.35 million, down by 595,000 people (-0.48%) from the previous year-marking the thirteenth consecutive annual decline. Male and female populations fell to 60.49 million (-0.44%) and 63.86 million (-0.51%), respectively. Natural population decline has persisted for 19 years among men and 15 years among women, reflecting ongoing demographic contraction. However, net migration trends offered some offset, with positive net migration among Japanese citizens for the first time in three years, alongside steady growth in the foreign resident population.
This demographic backdrop directly influences the autoimmune disease diagnostics market. Rheumatoid arthritis (RA), for instance, affects an estimated 822,000 people in Japan (Oxford University Press, May 2024), with peak prevalence among individuals aged 65-85. Given its higher occurrence in older adults, RA illustrates how aging demographics are driving demand for diagnostic services-particularly ANA tests, autoantibody panels, and confirmatory molecular assays.
Japan Autoimmune Disease Diagnostics Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the Japan autoimmune disease diagnostics market based on type, product, test type, and end use:
- Type Outlook (Revenue, USD Million, 2021 - 2033)
- Systemic autoimmune disease diagnostics
- Rheumatoid arthritis
- Ankylosing spondylitis diagnostics
- Systemic lupus erythematosus (SLE)
- Others
- Localized autoimmune disease diagnostics
- Multiple sclerosis
- Type 1 diabetes
- Hashimoto's Thyroiditis
- Idiopathic thrombocytopenic purpura
- Others
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Instruments
- Consumables & Assays
- Test Type Outlook (Revenue, USD Million, 2021 - 2033)
- Antinuclear antibody tests
- Indirect Immunofluorescence (IIF) ANA tests
- ELISA-based ANA tests
- Multiplex/line immunoassay ANA panels
- Others
- Autoantibody tests
- Rheumatoid Factor (RF) tests
- Anti-Cyclic Citrullinated Peptide (Anti-CCP) tests
- Anti-dsDNA tests
- Anti-Smith (Sm) antibody tests
- Anti-Ro/SSA & Anti-La/SSB antibody tests
- Others
- C-reactive Protein (CRP)
- Complete blood count (CBC)
- Urinalysis
- Others
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals
- Diagnostic Centers
- Others
Product Code: GVR-4-68040-738-6
Table of Contents
Chapter 1. Japan Autoimmune Disease Diagnostics Market: Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.1.1. Segment Definitions
- 1.1.1.1. Type Segment
- 1.1.1.2. Technology Segment
- 1.1.1.3. End Use Segment
- 1.1.1. Segment Definitions
- 1.2. Estimates and Forecast Timeline
- 1.3. Objectives
- 1.3.1. Objective - 1
- 1.3.2. Objective - 2
- 1.3.3. Objective - 3
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information or Data Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Validation
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. List of Abbreviations
Chapter 2. Japan Autoimmune Disease Diagnostics Market: Executive Summary
- 2.1. Market Snapshot
- 2.2. Type and Product Snapshot
- 2.3. Test Type and End Use Snapshot
- 2.4. Competitive Landscape Snapshot
Chapter 3. Japan Autoimmune Disease Diagnostics Market Variables, Trends, & Scope
- 3.1. Market Segmentation and Scope
- 3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
- 3.3. Market Dynamics
- 3.4. Market Drivers Analysis
- 3.4.1. Rising demand for early and non-invasive diagnosis
- 3.4.2. Technological advancements
- 3.4.3. Academic-industry collaborations
- 3.5. Market Restraint Analysis
- 3.5.1. High cost and limited reimbursement coverage
- 3.6. Market Opportunity Analysis
- 3.6.1. Expansion of personalized medicine and biomarker-based testing
- 3.7. Porter's Five Forces Analysis
- 3.8. PESTLE Analysis
Chapter 4. Japan Autoimmune Disease Diagnostics Market: Type Estimates & Trend Analysis
- 4.1. Japan Autoimmune Disease Diagnostics Market: Type Movement Analysis
- 4.2. Systemic autoimmune disease diagnostics
- 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.2.2. Rheumatoid arthritis
- 4.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.2.3. Ankylosing spondylitis diagnostics
- 4.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.2.4. Systemic lupus erythematosus (SLE)
- 4.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.2.5. Others
- 4.2.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3. Localized autoimmune disease diagnostics
- 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.2. Multiple sclerosis
- 4.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.3. Type 1 diabetes
- 4.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.4. Hashimoto's Thyroiditis
- 4.3.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.5. Idiopathic thrombocytopenic purpura
- 4.3.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.3.6. Others
- 4.3.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Japan Autoimmune Disease Diagnostics Market: Product Estimates & Trend Analysis
- 5.1. Japan Autoimmune Disease Diagnostics Market: Product Movement Analysis
- 5.2. Instruments
- 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.3. Consumables & Assays
- 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.4. Mass spectrometry-based assays
Chapter 6. Japan Autoimmune Disease Diagnostics Market: Test Type Estimates & Trend Analysis
- 6.1. Japan Autoimmune Disease Diagnostics Market: Test Type Movement Analysis
- 6.2. Antinuclear antibody tests
- 6.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.2.2. Indirect Immunofluorescence (IIF) ANA tests
- 6.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.2.3. ELISA-based ANA tests
- 6.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.2.4. Multiplex/line immunoassay ANA panels
- 6.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.2.5. Others
- 6.2.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3. Autoantibody tests
- 6.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.2. Rheumatoid Factor (RF) tests
- 6.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.3. Anti-Cyclic Citrullinated Peptide (Anti-CCP) tests
- 6.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.4. Anti-dsDNA tests
- 6.3.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.5. Anti-Smith (Sm) antibody tests
- 6.3.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.6. Anti-Ro/SSA & Anti-La/SSB antibody tests
- 6.3.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.7. Others
- 6.3.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4. C-reactive Protein (CRP)
- 6.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5. Complete blood count (CBC)
- 6.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6. Urinalysis
- 6.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.7. Others
- 6.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Japan Autoimmune Disease Diagnostics Market: End Use Estimates & Trend Analysis
- 7.1. Japan Autoimmune Disease Diagnostics Market: End Use Movement Analysis
- 7.2. Hospitals
- 7.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3. Diagnostic Centers
- 7.3.1. Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4. Others
- 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Company Categorization
- 8.2. Strategy Mapping
- 8.2.1. NEW PRODUCT LAUNCH
- 8.2.2. PARTNERSHIPS
- 8.2.3. ACQUISITION
- 8.2.4. COLLABORATION
- 8.2.5. FUNDING
- 8.3. Key Company Market Share Analysis, 2024
- 8.4. Company Heat Map Analysis
- 8.5. Company Profiles
- 8.5.1. Fujirebio
- 8.5.2. SEKISUI MEDICAL CO., LTD
- 8.5.2.1. Company Overview
- 8.5.2.2. Financial Performance
- 8.5.2.3. Product Benchmarking
- 8.5.2.4. Strategic Initiatives
- 8.5.3. Medical & Biological Laboratories (MBL)
- 8.5.3.1. Company Overview
- 8.5.3.2. Financial Performance
- 8.5.3.3. Product Benchmarking
- 8.5.3.4. Strategic Initiatives
- 8.5.4. Bio-Rad Laboratories, Inc.
- 8.5.4.1. Company Overview
- 8.5.4.2. Financial Performance
- 8.5.4.3. Product Benchmarking
- 8.5.4.4. Strategic Initiatives
- 8.5.5. Abbott
- 8.5.5.1. Company Overview
- 8.5.5.2. Financial Performance
- 8.5.5.3. Product Benchmarking
- 8.5.5.4. Strategic Initiatives
- 8.5.6. F. Hoffmann-La Roche, Ltd.
- 8.5.6.1. Overview
- 8.5.6.2. Financial Performance
- 8.5.6.3. Product Benchmarking
- 8.5.6.4. Strategic Initiatives
- 8.5.7. Siemens Healthineers AG
- 8.5.7.1. Company Overview
- 8.5.7.2. Financial Performance
- 8.5.7.3. Product Benchmarking
- 8.5.7.4. Strategic Initiatives
- 8.5.8. Sysmex Corporation
- 8.5.8.1. Grifols Company Overview
- 8.5.8.2. Financial Performance
- 8.5.8.3. Product Benchmarking
- 8.5.8.4. Strategic Initiatives
- 8.5.9. BioMerieux
- 8.5.9.1. Company Overview
- 8.5.9.2. Financial Performance
- 8.5.9.3. Product Benchmarking
- 8.5.9.4. Strategic Initiatives
- 8.5.10. Beckman Coulter ( Danaher)
- 8.5.10.1. Company Overview
- 8.5.10.2. Financial Performance
- 8.5.10.3. Product Benchmarking
- 8.5.10.4. Strategic Initiatives
Product Code: GVR-4-68040-738-6
List of Tables
- Table 1 List 0f Abbreviation
- Table 2 Japan Autoimmune Disease Diagnostics Market, By Type, 2021 - 2033 (USD Million)
- Table 3 Japan Autoimmune Disease Diagnostics Market, By Product, 2021 - 2033 (USD Million)
- Table 4 Japan Autoimmune Disease Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
- Table 5 Japan Autoimmune Disease Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
List of Figures
- Fig. 1 Market research process
- Fig. 2 Information procurement
- Fig. 3 Market summary
- Fig. 4 Market segmentation & scope
- Fig. 5 Market size and growth prospects
- Fig. 6 Japan autoimmune disease diagnostics market - Key market driver analysis
- Fig. 7 Japan autoimmune disease diagnostics market - Key market restraint analysis
- Fig. 8 Penetration & growth prospect mapping
- Fig. 9 Japan autoimmune disease diagnostics market - Porter's analysis
- Fig. 10 Japan autoimmune disease diagnostics market - PESTEL analysis
- Fig. 11 Japan autoimmune disease diagnostics market Type outlook key takeaways
- Fig. 12 Japan autoimmune disease diagnostics market : Type movement analysis
- Fig. 13 Systemic autoimmune disease diagnostics market estimates, 2021 - 2033 (USD Million)
- Fig. 14 Rheumatoid arthritis market estimates, 2021 - 2033 (USD Million)
- Fig. 15 Ankylosing spondylitis diagnostics market estimates, 2021 - 2033 (USD Million)
- Fig. 16 Localized autoimmune disease diagnostics market estimates, 2021 - 2033 (USD Million)
- Fig. 17 Multiple sclerosis market estimates, 2021 - 2033 (USD Million)
- Fig. 18 Type 1 diabetes market estimates, 2021 - 2033 (USD Million)
- Fig. 19 Hashimoto's Thyroiditis market estimates, 2021 - 2033 (USD Million)
- Fig. 20 Idiopathic thrombocytopenic purpura market estimates, 2021 - 2033 (USD Million)
- Fig. 21 Others market estimates, 2021 - 2033 (USD Million)
- Fig. 22 Japan autoimmune disease diagnostics market product outlook key takeaways
- Fig. 23 Japan autoimmune disease diagnostics market : product movement analysis
- Fig. 24 Instruments market estimates, 2021 - 2033 (USD Million)
- Fig. 25 Consumables & Assays market estimates, 2021 - 2033 (USD Million)
- Fig. 26 Japan autoimmune disease diagnostics market Test type outlook key takeaways
- Fig. 27 Japan autoimmune disease diagnostics market : Test type movement analysis
- Fig. 28 Antinuclear antibody tests market estimates, 2021 - 2033 (USD Million)
- Fig. 29 Indirect Immunofluorescence (IIF) ANA tests market estimates, 2021 - 2033 (USD Million)
- Fig. 30 ELISA-based ANA tests market estimates, 2021 - 2033 (USD Million)
- Fig. 31 Multiplex/line immunoassay ANA panels market estimates, 2021 - 2033 (USD Million)
- Fig. 32 Others market estimates, 2021 - 2033 (USD Million)
- Fig. 33 Autoantibody tests market estimates, 2021 - 2033 (USD Million)
- Fig. 34 Rheumatoid Factor (RF) tests estimates, 2021 - 2033 (USD Million)
- Fig. 35 Anti-Cyclic Citrullinated Peptide (Anti-CCP) tests estimates, 2021 - 2033 (USD Million)
- Fig. 36 Anti-dsDNA tests estimates, 2021 - 2033 (USD Million)
- Fig. 37 Anti-Smith (Sm) antibody tests estimates, 2021 - 2033 (USD Million)
- Fig. 38 Anti-Ro/SSA & Anti-La/SSB antibody tests estimates, 2021 - 2033 (USD Million)
- Fig. 39 Others estimates, 2021 - 2033 (USD Million)
- Fig. 40 C-reactive Protein (CRP) market estimates, 2021 - 2033 (USD Million)
- Fig. 41 Complete blood count (CBC) market estimates, 2021 - 2033 (USD Million)
- Fig. 42 Urinalysis market estimates, 2021 - 2033 (USD Million)
- Fig. 43 Others market estimates, 2021 - 2033 (USD Million)
- Fig. 44 Japan autoimmune disease diagnostics market end use outlook key takeaways
- Fig. 45 Japan autoimmune disease diagnostics market : end use movement analysis
- Fig. 46 Hospitals market estimates, 2021 - 2033 (USD Million)
- Fig. 47 Diagnostic Centers market estimates, 2021 - 2033 (USD Million)
- Fig. 48 Others market estimates, 2021 - 2033 (USD Million)
- Fig. 49 Strategy framework
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.